Dianthus Therapeutics
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7 Times Sq Fl 43, New York, New York, 10...Phone Number
(929) 999-4055Website
www.dianthustx.comRevenue
<$5 MillionStock Symbol
DNTHIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
2
2
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.Explore more
Dianthus Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dianthus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Dianthus Therapeutics had a recent Job posting/layoffs
Dianthus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Dianthus Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Dianthus Therapeutics has new funding data
Check if Dianthus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Dianthus Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Dianthus Therapeutics
Check out if Dianthus Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Dianthus Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Dianthus Therapeutics
Compare insights from companies similar to Dianthus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dianthus Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dianthus Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dianthus Therapeutics.
Dianthus Therapeutics Tech Stack
A closer look at the technologies used by Dianthus Therapeutics
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Stake & Stock Ownership, Finance
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Dianthus Therapeutics News & Media
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanismsDianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptaDianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptanDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Dianthus Therapeutics
Sign Up For FreeTo access detailed company insights
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-gener... Read More
